Frank Xiaoqing Liu

Merck (Germany) — Germany

Economics, Econometrics and Finance · Social Sciences

22h-index1.4kcitations58works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(23), Cancer Immunotherapy and Biomarkers(19), Dialysis and Renal Disease Management(15), CAR-T cell therapy research(15), Economic and Financial Impacts of Cancer(12)

Publications58 total

U.S. health utility in advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 (METex14) skipping mutations treated with tepotinib.
Journal of Clinical Oncology·2021
Financial impact of tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer bearing <i>MET</i>ex14 skipping in the United States.
Journal of Clinical Oncology·2021· 1 cited
Healthcare resource utilization (HCRU), costs, and mortality in relation to select immune-related adverse events (irAEs) and line of therapy (LOT) in patients (pts) with advanced or metastatic urothelial cancer (UC) treated with immune checkpoint inhibitor (ICI) monotherapy.
Journal of Clinical Oncology·2021· 1 cited
Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring <i>MET</i>ex14 skipping alterations in the United States
Journal of Medical Economics·2021· 7 citedOpen Access
Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel: Study informing treatment pathway decisions in Merkel cell carcinoma (MCC).
Journal of Clinical Oncology·2020· 3 cited
Clinical impact of early progression among patients (Pts) with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs) in first-line (1L) setting: IMPACT RCC real-world study.
Journal of Clinical Oncology·2020
Immune-related adverse events (irAEs) among urothelial carcinoma (UC) patients treated with PD-1 VS PD-L1 inhibitors: A real-world observational study.
Journal of Clinical Oncology·2020
Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel –Study informing treatment Pathway dEcisions in Merkel cell cARcinoma (MCC).
Journal of Clinical Oncology·2020
Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings
Quality of Life Research·2020· 22 citedOpen Access
HSR20-096: Budget Impact Analysis of Avelumab Plus Axitinib for the First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Journal of the National Comprehensive Cancer Network·2020
Treatment duration and response of advanced renal cell carcinoma (aRCC) patients (pts) who have completed first-line (1L) treatment (tx): Results from a cross-sectional real-world study.
Journal of Clinical Oncology·2020
Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers
Journal of Medical Economics·2019· 9 citedOpen Access
Real-world treatment patterns and clinical outcomes among patients with advanced melanoma
Medicine·2019· 31 citedOpen Access
Real-world experience with pembrolizumab in patients with advanced melanoma
Medicine·2019· 38 citedOpen Access
Health-related quality of life (HRQoL) in patients with advanced melanoma receiving immunotherapies across real-world clinical practice settings.
Journal of Clinical Oncology·2019· 1 cited
Health care resource utilization in patients with advanced melanoma receiving immunotherapies in the real world.
Journal of Clinical Oncology·2019
Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
Journal of Medical Economics·2019· 28 citedOpen Access
Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States
Journal of Managed Care & Specialty Pharmacy·2019· 13 citedOpen Access
Healthcare resource utilization in first-line immunotherapies for patients with metastatic melanoma.
Journal of Clinical Oncology·2019
HSR19-095: Healthcare Resource Utilization and Costs in Patients Treated with Systemic Therapies in Metastatic Melanoma
Journal of the National Comprehensive Cancer Network·2019
page 1 of 3Next →

Frequent Co-authors

Scott J. Diede(7), Richard W. Joseph(7), Cynthia Macahilig(6), Robin S. Turpin(5), Bartosz Chmielowski(5), Alicia C. Shillington(5), Vaidehi Dave(5), Qing Harshaw(5), Catherine J. Mercaldi(4), Murat Arıcı(4), Mo Yang(4), Ruth Kim(4), Gary Inglese(3), James M. Pellissier(3), Thomas Burke(3), Ruifeng Xu(3), Xiting Cao(3), Alessandro Pontes‐Arruda(3), Surrey M. Walton(3), Catrin Treharne(3)